PT - JOURNAL ARTICLE AU - G Edan AU - G Comi AU - E Le Page AU - E Leray AU - M A Rocca AU - M Filippi AU - for The French–Italian Mitoxantrone Interferon-beta-1b Trial Group TI - Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial AID - 10.1136/jnnp.2010.229724 DP - 2011 Dec 01 TA - Journal of Neurology, Neurosurgery & Psychiatry PG - 1344--1350 VI - 82 IP - 12 4099 - http://jnnp.bmj.com/content/82/12/1344.short 4100 - http://jnnp.bmj.com/content/82/12/1344.full SO - J Neurol Neurosurg Psychiatry2011 Dec 01; 82 AB - Objectives The long-term impact of interferon-beta-1b (IFN) might be improved by short-term immunosuppression with mitoxantrone (MITOX) in aggressive relapsing-remitting multiple sclerosis (ARMS) patients.Methods In this 3-year clinical and MRI study, 109 ARMS patients (two or more relapses in the previous 12 months and one or more gadolinium (Gd)-enhancing MRI lesion) were randomised into two groups: 54 patients received MITOX monthly (12 mg/m2; maximum 20 mg) combined with 1 g of methylprednisolone (MP) for 6 months followed by IFN for the last 27 months, and 55 patients received IFN for 3 years combined with 1 g of MP monthly for the first 6 months. The primary endpoint was the time to worsen by at least one Expanded Disability Status Scale point confirmed at 3 months.Results The time to worsen by at least one Expanded Disability Status Scale point confirmed at 3 months was delayed by 18 months in the MITOX group compared with the IFN group (p<0.012). The 3-year risk of worsening disability was reduced by 65% in the MITOX group relative to the IFN group (11.8% vs 33.6%). MITOX patients had a reduced relapse rate by 61.7%, a reduced number of Gd-enhancing lesions at month 9 and a slower accumulation of new T2 lesions at each time point.Conclusions Although there were limitations in this investigator–academic-driven study, the data do suggest that mitoxantrone induction therapy prior to INF beta-1b may have a role in aggressive disease.